A British startup in the health tech space has unveiled an artificial intelligence (AI) platform that can analyze MRI scans for early disease detection. The company’s approach, using imaging biomarkers, promises improved decision-making in disease diagnosis and treatment.
Twinn Health, backed by a $500 million venture capital fund from Saudi Aramco, says it is making strides in longevity and preventive healthcare.
MRI technology has long been an instrumental tool in the healthcare industry. Although AI advancements have begun to facilitate the detection of specific conditions within MRI scans, the broader application in disease detection and augmenting longevity remains nascent.
“Usually, when you do an MRI today, it’s one MRI scan for one single diagnosis,” Wareed Alenaini, founder and CEO of Twinn Health, explains in an interview with Longetivy Technology, citing kidney stones as an example.
“You do the MRI, the doctor looks at the kidney stones, writes the report, and then the scan data gets archived, and will probably never be checked again,” Alenaini continues. “That’s where Twinn comes in: we’re extracting additional insights from MRI scans that may not have been the primary focus of the physician.”
Go to Source to See Full Article
Author: Decrypt AI, Edited by Ryan Ozawa
Tip BTC Newswire with Cryptocurrency